Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Novel HCK inhibitor has a synergistic effect with azacytidine or cytarabine in AML cells

Sara Olalla Saad • 7 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia Azacitidine Cytarabine

Sara Olalla Saad, PhD, University of Campinas & Hemocentro – Unicamp, Campinas, Brazil, discusses a novel chemical compound inhibitor of hematopoietic cell kinase (HCK). She explains how this was found to have antiproliferative activity in leukemic cells without altering the cell death and survival rate of normal cells, having a synergistic effect with azacitidine or cytarabine, for acute myeloid leukemia (AML), and discusses how they are moving testing of this agent forwards. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Sara Olalla Saad

3:16
Targeting NRF2 with quercetin in AML
Sara Olalla Saad • 8 Dec 2019
6:23
FIBROMET preliminary results: metformin promising for primary MF
Sara Olalla Saad • 8 Dec 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals